SCHEMBL6170420

SCHEMBL6170420

Cc1ccc(-c2noc(C)c2-c2ccc(S(N)(=O)=O)cc2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 16/20 0.82
PTGS1 P23219 4/20 0.82
MT-CO2 P00403 3/20 0.82
CA12 O43570 2/20 0.82
CA1 P00915 2/20 0.82
CA2 P00918 2/20 0.82
CA3 P07451 2/20 0.82
CA6 P23280 2/20 0.82
CA5A P35218 2/20 0.82
CA7 P43166 2/20 0.82
CA9 Q16790 2/20 0.82
CA5B Q9Y2D0 2/20 0.82
LMNA P02545 1/20 0.82
ADRB2 P07550 1/20 0.82
ADRB1 P08588 1/20 0.82
CYP3A4 P08684 1/20 0.82
ADORA3 P0DMS8 1/20 0.82
CHRM1 P11229 1/20 0.82
ADRA2B P18089 1/20 0.82
CA4 P22748 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valdecoxib SCHEMBL3356 0.90 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6168344 0.90 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
Valdecoxib SCHEMBL3853130 0.90 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
Valdecoxib SCHEMBL6601157 0.89 PTGS2 (0.97) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL14267686 0.89 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL7799111 0.89 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA12CA1
Valdecoxib SCHEMBL5999213 0.89 PTGS2 (0.97) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL4888365 0.89 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL4800858 0.89 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6168350 0.89 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11253600-B2 Bioorthogonal compositions TAMBO, INC. (US) 2022-02-22 US disclosed
US-20210128733-A1 BIOORTHOGONAL COMPOSITIONS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2021-05-06 US disclosed
EP-2335699-B1 SYNERGISTIC COMBINATION OF ANALGESIC COMPOUNDS BIOCODEX (FR) 2016-03-30 EP disclosed
EP-2335699-A1 Synergistic combination of analgesic compounds Biocodex (FR) 2011-06-22 EP disclosed
US-20110136885-A1 Synergistic Combination of Analgesic Compounds BIOCODEX (FR) 2011-06-09 US disclosed
US-20110136885-A1 Synergistic Combination of Analgesic Compounds BIOCODEX (FR) 2011-06-09 US disclosed
US-20070060629-A1 Large conductance calcium-activated k channel opener TANABE SEIYAKU CO., LTD. (JP) 2007-03-15 US disclosed
CN-1214790-C Medicinal composition for treating inflammation SEARLE & CO (US) 2005-08-17 CN disclosed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
US-5985902-A TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISORDERS, SUCH AS ARTHRITIS G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
US-5633272-A Substituted isoxazoles for the treatment of inflammation PHARMACIA & UPJOHN COMPANY LLC 1997-05-27 US disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136885-A1 Synergistic Combination of Analgesic Compounds PTGES2, PTGS2, OPRK1 PTGS2 2/4885PTGS1 6/4885MT-CO2 466/4885
US-20210128733-A1 BIOORTHOGONAL COMPOSITIONS TIE1, BBOX1, ST14 PTGS2 570/4885PTGS1 618/4885MT-CO2 3622/4885
US-20070060629-A1 Large conductance calcium-activated k channel opener KCNN3, KCNN1, KCNN2 PTGS2 594/4885PTGS1 558/4885MT-CO2 1536/4885
US-11253600-B2 Bioorthogonal compositions TIE1, BBOX1, ST14 PTGS2 570/4885PTGS1 618/4885MT-CO2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.